Clinical Applications Specialist 1

Who owns Moderna right now in 2026? Moderna is publicly traded and widely held, not controlled by a family, state, or private equity sponsor. That makes who owns Moderna easier to see in filings, and it keeps control tied to the market rather than a single block holder. Moderna trades on the NASDAQ stock exchange under the ticker symbol MRNA and is a component of the S&P 500 index. The largest individual insider shareholders of Moderna are Stéphane Bancel (CEO) with approximately 7.3%, Noubar Afeyan (Co-founder and Chairman) with approximately 5%, Robert S. Langer (Co-founder) with approximately 4%, and Stephen Hoge (President) with approximately 1.3%. On the institutional side, the largest institutional shareholders of Moderna include Vanguard Group Inc., BlackRock, Inc., FMR LLC (Fidelity), Baillie Gifford & Co., State Street Corp., Capital World Investors, Geode Capital Management, and Morgan Stanley. No single person or entity controls Moderna outright. It is a widely distributed public company where the biggest voices are large index funds and asset managers - the same institutional giants that dominate most large American public companies. Ownership and key stakeholders table. The origin story: A conversation that changed medicine. Moderna was founded in 2010 by Noubar Afeyan, founder and CEO of Flagship Pioneering, in collaboration with Robert Langer, a professor of chemical engineering at MIT, and Derrick Rossi, a stem cell biologist, with the aim of developing messenger RNA (mRNA) therapeutics as a novel drug modality. The company originated from exploratory work within Flagship's VentureLabs, initially codenamed LS18, and was renamed Moderna Therapeutics to reflect its focus on modified RNA technologies. The spark was a meeting between Noubar Afeyan and Derrick Rossi, who had been doing breakthrough research on using chemically modified mRNA to reprogram cells. Noubar Afeyan met with Bob Langer and Derrick Rossi to review recent data on the use of chemically modified mRNA to reprogram adult human fibroblast cells into induced pluripotent stem cells. Noubar envisioned a different use of engineered mRNA as a new kind of medicine and launched within Flagship's VentureLabs group a month-long exploration which eventually led to Newco LS18, Inc. - which became Moderna. Stéphane Bancel, who had been Chief Executive Officer of the French diagnostics company bioMérieux SA, joined Moderna's board of directors in March 2011, and became its CEO in October 2011. Bancel was the operational genius who took a brilliant scientific idea and turned it into a scalable company. Under his leadership, Moderna secured partnerships, built laboratories, raised hundreds of millions of dollars, and survived years of skepticism from the broader scientific and investment community - many of whom believed mRNA medicine was too speculative to ever work. The COVID-19 moment that changed everything. For its first decade, Moderna was known only within the biotechnology world. Then came 2020 - and everything changed overnight. When SARS-CoV-2 emerged in early 2020, Moderna's scientists began designing a vaccine within days of the viral genome being published. The mRNA platform they had spent a decade building was perfectly suited for the task - because instead of growing virus in a lab to make a traditional vaccine, Moderna just needed to encode the spike protein instructions into mRNA and inject them. Moderna received an award from U.S. government agency BARDA for up to $483 million to accelerate development. It then announced a supply agreement with the U.S. government for an initial 100 million doses of its COVID-19 vaccine. The result was Spikevax - one of the first two mRNA COVID-19 vaccines in history - which achieved 94.5% efficacy in clinical trials and was authorized for emergency use by the FDA in December 2020. Almost overnight, Moderna went from a well-funded biotech startup to one of the most important companies in the world. The IPO and the Road to the S&P 500. Moderna became a public company through its 2018 IPO, which opened the cap table to public investors and shifted control from founders to shareholders. At the time of its IPO, Moderna had never had a single approved product. It went public purely on the strength of its mRNA platform and pipeline - an extraordinary level of investor conviction. The 2018 IPO raised approximately $600 million - the largest biotech IPO in history at that time. The underwriters priced shares at $23 each. By the peak of the COVID-19 vaccine rollout in 2021, MRNA shares had hit $497 - a gain of more than 2,000% in under three years. That surge created enormous paper wealth for the founders. Stéphane Bancel's net worth briefly exceeded $10 billion at the peak. Noubar Afeyan and Robert Langer also saw their stakes become worth billions. The Moderna story had become one of the greatest wealth-creation events in biotechnology history. Where is Moderna today in 2026? The post-COVID world has been a harder one for Moderna. Demand for COVID-19 vaccines has normalized dramatically, and the company has posted significant losses as it works to build out its broader pipeline. Moderna reported revenue of $1.94 billion in 2025, with a net loss of $2.8 billion and total assets of $12.3 billion. The company employs approximately 4,800 people. But Moderna's pipeline tells a more optimistic story. The company is advancing mRNA-based cancer vaccines - personalized treatments designed specifically for an individual patient's tumor - and has reported promising early results in trials with Merck. CEO Stéphane Bancel stated in early 2026: "I believe 2026 will also be the year when the world sees the promise of Moderna as a leading oncology company." In August 2026, the FDA approved Moderna's new mRNA-based flu vaccine - the first mRNA flu shot available to the public - marking another major milestone in the company's mission to use mRNA to fight a wide range of diseases beyond COVID-19. Frequently asked questions (faqs). Q1. Who owns Moderna in 2026? Moderna (NASDAQ: MRNA) is publicly owned with no single controlling shareholder - Vanguard and BlackRock are the largest institutional holders. Q2. Who founded Moderna? Moderna was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer, backed by Flagship Pioneering. Q3. Who is the CEO of Moderna in 2026? Stéphane Bancel is the CEO of Moderna, a role he has held since October 2011 after being recruited by co-founder Noubar Afeyan. Q4. What percentage of Moderna does Stéphane Bancel own? Stéphane Bancel owns approximately 7.3% of Moderna, making him the largest individual insider shareholder. Q5. When did Moderna go public? Moderna held its IPO in December 2018 on NASDAQ, pricing shares at $23 - the largest biotech IPO in history at that time. Q6. What is Moderna's revenue in 2025? Moderna reported $1.94 billion in revenue for 2025, with a net loss of $2.8 billion as it funds its broader pipeline beyond COVID-19 vaccines. Q7. Does the U.S. government own part of Moderna? No. The U.S. government funded Moderna's COVID-19 vaccine development through BARDA grants and supply agreements but holds no equity ownership in the company. Q8. What new products is Moderna launching in 2026? In August 2026, the FDA approved Moderna's first mRNA-based flu vaccine - and the company is advancing personalized mRNA cancer vaccines in partnership with Merck. Moderna is a publicly traded company on NASDAQ (ticker: MRNA) with no single controlling owner. It was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer - backed from day one by Flagship Pioneering, the venture capital firm that incubated the entire concept. The largest individual insider shareholders today are CEO Stéphane Bancel (~7.3%), Co-founder and Chairman Noubar Afeyan (~5%), and Co-founder Robert Langer (~4%). The biggest institutional holders are Vanguard, BlackRock, Fidelity, and Baillie Gifford. No single entity holds majority control - making Moderna a true public company, accountable to its broad shareholder base. From a codenamed startup experiment in 2010 to a COVID-19 vaccine that reached hundreds of millions of people, to an mRNA flu shot approved by the FDA in 2026 - Moderna's story is far from over.

bioMérieux highlights positive impacts of rapid, accurate diagnostics for Patients and accepts industry awards at ADLM 2026. Aug 07, 2026, 14:10 ET SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ - bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo for an important conversation about the impact of access to diagnostics while also accepting multiple IMV ServiceTrak(TM) awards. PRESS CONFERENCE The company hosted a press panel, The Power of Diagnostics: How Delays Impact Patients and Providers, to discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system. Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer at bioMérieux, moderated the panel with: * Dr. Omai Garner, Clinical Professor and Director of Clinical Microbiology, UCLA; * Dr. Michael Astion, PhD, Medical Director, Regional Laboratories and Point of Care, Medical Director, Reference Laboratories and PLUGS (Patient-Centered Laboratory Utilization Guidance Services), Department of Laboratories, Seattle Children's Hospital, Professor of Laboratory Medicine and Pathology, University of Washington; * Helaine Bader, MPH Vice President of Education, HealthyWomen; and * Dr. John Hurst, Senior Director, Field Medical Affairs at bioMérieux. Dr. Cooper noted that the panel discussed the "tremendous amount of pressure health care systems face and how access to rapid diagnostics at the point of care often alleviates some of this stress by getting health care clinicians and their patients answers while they wait." "Delay in getting a diagnosis may result in patients not receiving treatment at all because they may not come back for follow-up," said Ms. Bader. "Faster time to diagnosis during a single visit not only provides the patient with immediate answers but also builds trust between the patient and provider and reduces patient frustration, potential complications from the infection and the need for repeat visits." INDUSTRY RECOGNITION During the show, bioMérieux also accepted seven 2026 IMV ServiceTrak(TM) Clinical Laboratory Awards. These awards highlight bioMérieux's continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories. 2026 ServiceTrak Awards: ID/AST Systems * Best Customer Satisfaction * Best System Performance * Best Service 2026 ServiceTrak Awards: Blood Culture Systems * Best Customer Satisfaction * Best System Performance * Best Service 2026 Best System Performance * Immunoassay Analyzers "We are thrilled that IMV and the Science and Medicine Group has recognized bioMérieux for the ninth consecutive year for the continued dedication and excellence of our product management, operations, and customer support teams," said Randy Pritchard, General Manager and Sr. Vice President of Clinical Operations, bioMérieux. "This recognition, across our immunoassay, ID/AST Systems, and Blood Culture Systems offerings, highlights our commitment to pioneering diagnostics in the fight against sepsis and antimicrobial resistance." ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. www.biomerieux.com. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP SOURCE bioMérieux

bioMérieux to Showcase Company's Latest in Diagnostic Innovations at ADLM 2026. PR Newswire Today at 8:43am PDT ANAHEIM, Calif., July 14, 2026 /PRNewswire/ - bioMérieux, a global leader in in vitro diagnostics, today announced it will showcase its latest diagnostic solutions and innovations at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo, taking place in Anaheim, California, July 26 through 30. Attendees are invited to visit bioMérieux at booth #2501 in Hall B to explore the company's comprehensive portfolio and connect with experts across clinical microbiology, molecular diagnostics, and laboratory informatics. Featured Technologies at Booth #2501 This year's company presence is anchored by the theme: "A legacy of diagnostic leadership. Your partner for what's ahead." The theme reflects bioMérieux's continued commitment to advancing diagnostic excellence over the past 63 years, while supporting laboratories and healthcare practitioners in navigating the future of medicine. At the expo, bioMérieux will highlight a range of innovative platforms designed to showcase the company's end-to-end laboratory ecosystem including: BIOFIRE(R) FILMARRAY(R) TORCH System, a multiplex PCR technology that tests for a comprehensive group of targets in about an hour, BIOFIRE(R) SPOTFIRE(R) System, a multiplex PCR platform that brings reliable diagnostics to point-of-care clinical settings, VITEK(R) MS PRIME, a mass spectrometry system for routine microbial identification, and the VIDAS(R) 3, an automated benchtop immunoassay system. Visitors will be able to explore how bioMérieux's solutions connect microbiology, molecular diagnostics, laboratory automation, informatics, and stewardship initiatives to help laboratories improve efficiency, accelerate decision-making, and optimize patient care. In addition, visitors can explore bioMérieux's latest data and IT solutions, and Lab Consultancy offerings, designed to help laboratories optimize operations, improve outcomes, and drive digital transformation. Educational Symposiums As part of its commitment to advancing clinical knowledge and best practices, and demonstrating the value of diagnostics, bioMérieux will host two symposiums included in the conference's agenda: * From Central Lab to POC: Rethinking Vaginitis Diagnostics * Tuesday, July 28 from 12:00 p.m. until 12:20 p.m. in Exhibit Hall Theater 2 * Attendees will examine current diagnostic limitations, the consequences of delayed results, and how point-of-care testing aligns with real-time decision making. * The Syndromic Standard: Explore the Clinical Impact of MPCR GI Panels for Gastroenteritis * Tuesday, July 28 from 2:45 p.m. until 3:35 p.m. in Exhibit Hall Theater 1 * Attendees will learn about the latest developments in reducing diagnostic uncertainty, improving time-to-treatment, and advancing patient outcomes. Press Conference and Panel Discussion The company will also host a press conference panel, The Power of Diagnostics: How Delays Impact Patients and Providers, on Wednesday, July 29 from 9:00 a.m. until 9:45 a.m. in room 213D. Panel experts from bioMérieux, rural medicine, and patient advocacy will discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system, especially as they affect women, minority communities, and other underserved populations. The panel will feature real-world examples from patient and provider experiences and potential solutions for today and the future. Conference attendees and members of the media are invited to attend. For media looking to register for event credentials: visit https://myadlm.org/media/press-registration. For more information on the bioMérieux press conference contact: [email protected]. ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP SOURCE bioMerieux This is a paid placement. For further inquiries, please contact PR Newswire directly.